Evidence map›Paper›PMID 29754588›Full record

ArticleInfectious diseases of poverty2018

Evaluating seroprevalence to circumsporozoite protein to estimate exposure to three species of Plasmodium in the Brazilian Amazon.

Virginia Araujo Pereira, Juan Camilo Sánchez-Arcila, Mariana Pinheiro Alves Vasconcelos, Amanda Ribeiro Ferreira, Lorene de Souza Videira, Antonio Teva, Daiana Perce-da-Silva, Maria Teresa Queiroz Marques, Luzia Helena de Carvalho, Dalma Maria Banic and 2 more

Open access · goldAbstract read
In one paragraph

Article in Infectious diseases of poverty, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Using Serological Markers for the Surveillance ofPathogens (Basel, Switzerland) · 2023
    Article
  3. IgM antibody responses againstFrontiers in cellular and infection microbiology · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Antibody Responses AgainstFrontiers in immunology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Virginia Araujo PereiraLaboratory of Immunoparasitology, Oswaldo Cruz Institute/Fiocruz, Av. Brasil 4365, Manguinhos, Rio de Janeiro, Brazil.
Juan Camilo Sánchez-ArcilaLaboratory of Immunoparasitology, Oswaldo Cruz Institute/Fiocruz, Av. Brasil 4365, Manguinhos, Rio de Janeiro, Brazil.
Mariana Pinheiro Alves VasconcelosInstitute of Infectology Emilio Ribas, São Paulo, São Paulo, Brazil.
Amanda Ribeiro FerreiraLaboratory of Immunoparasitology, Oswaldo Cruz Institute/Fiocruz, Av. Brasil 4365, Manguinhos, Rio de Janeiro, Brazil.
Lorene de Souza VideiraLaboratory of Immunoparasitology, Oswaldo Cruz Institute/Fiocruz, Av. Brasil 4365, Manguinhos, Rio de Janeiro, Brazil.
Antonio TevaLaboratory of Immunodiagnosis, Departament of Biological Sciences, National School of Public Health/Fiocruz, Rio de Janeiro, Brazil.
Daiana Perce-da-SilvaLaboratory of Clinical Immunology, Oswaldo Cruz Institute/Fiocruz, Rio de Janeiro, Brazil.
Maria Teresa Queiroz MarquesLaboratory of Histocompatibility and Cryopreservation - HLA of DHE/IBRAG/UERJ, Rio de Janeiro, Brazil.
Luzia Helena de CarvalhoMolecular Biology and Malaria Immunology Research Group, Centro de Pesquisas René Rachou/Fiocruz, Belo Horizonte, Minas Gerais, Brazil.
Dalma Maria BanicLaboratory of Clinical Immunology, Oswaldo Cruz Institute/Fiocruz, Rio de Janeiro, Brazil.
Luiz Cristóvão Sobrino PôrtoLaboratory of Histocompatibility and Cryopreservation - HLA of DHE/IBRAG/UERJ, Rio de Janeiro, Brazil.
Joseli Oliveira-FerreiraLaboratory of Immunoparasitology, Oswaldo Cruz Institute/Fiocruz, Av. Brasil 4365, Manguinhos, Rio de Janeiro, Brazil. lila@ioc.fiocruz.br.
Fundação Oswaldo Cruz · BRUniversidade do Estado do Rio de Janeiro · BRInstituto de Infectologia Emílio Ribas · BR

Funding

CNPq Fellowship 142104/2014-0Fundação de Amparo à Pesquisa do Rio de Janeiro- FAPERJ E-26/170.003/2010PRONEX Rede Malaria, Conselho Nacional de Pesquisa e Tecnologia - CNPq 5555659/2009-7Research Productivity Fellowships from the CNPq 307659/2016-0
6 · The paper itself

Abstract

backgroundBrazil has seen a great decline in malaria and the country is moving towards elimination. However, for eventual elimination, the control program needs efficient tools in order to monitor malaria exposure and transmission. In this study, we aimed to evaluate whether seroprevalence to the circumsporozoite protein (CSP) is a good tool for monitoring the exposure to and/or evaluating the burden and distribution of Plasmodium species in the Brazilian Amazon.

methodsCross-sectional surveys were conducted in a rural area of Porto Velho, Rondônia state. Parasite infection was detected by microscopy and polymerase chain reaction. Antibodies to the sporozoite CSP repeats of Plasmodium vivax, P. falciparum, and P. malariae (PvCS, PfCS, and PmCS) were detected using the enzyme-linked immunosorbent assay technique. Human leukocyte antigen (HLA)-DRB1 and DQB1 genes were typed using Luminex® xMAP® technology.

resultsThe prevalence of immunoglobulin G against P. vivax CSP peptide (62%) was higher than P. falciparum (49%) and P. malariae (46%) CSP peptide. Most of the studied individuals had antibodies to at least one of the three peptides (72%), 34% had antibodies to all three peptides and 28% were non-responders. Although the majority of the population was not infected at the time of the survey, 74.3% of parasite-negative individuals had antibodies to at least one of the CSPs. Importantly, among individuals carrying the haplotypes DRB1*04~DQB1*03, there was a significantly higher frequency of PfCS responders, and DRB1*16~DQB1*03 haplotype for PvCS and PfCS responders. In contrast, HLA-DRB1*01 and HLA-DQB1*05 allelic groups were associated with a lack of antibodies to P. vivax and P. falciparum CSP repeats, and the haplotype DRB1*01~DQB1*05 was also associated with non-responders, including non-responders to P. malariae.

conclusionsOur results show that in low transmission settings, naturally acquired antibody responses against the CSP repeats of P. vivax, P. falciparum, and P. malariae in a single cross-sectional study may not represent a valuable marker for monitoring recent malaria exposure, especially in an area with a high prevalence of P. vivax. Furthermore, HLA class II molecules play an important role in antibody response and require further study with a larger sample size. It will be of interest to consider HLA analysis when using serosurveillance to monitor malaria exposure among genetically diverse populations.

Indexed as

AdolescentAdultAntibodies, ProtozoanBrazilCross-Sectional StudiesFemaleHumansMalariaMaleMiddle AgedPlasmodiumPrevalenceProtozoan ProteinsRural PopulationSeroepidemiologic StudiesSpecies SpecificityAntibodies, Protozoancircumsporozoite protein, ProtozoanProtozoan ProteinsBrazilCircumsporozoite proteinHuman leucocyte antigenIgG antibodyMalariaPorto VelhoRondôniaSerological marker

Identifiers

PMID29754588
PMCPMC5950184
OpenAlexW2804733726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.